HIGHLIGHTS
- who: Meiping Lu from the National Institute of Environmental Health Sciences (NIH), United States Istanbul University-Cerrahpasu0327a, Turkey have published the research: Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis, in the Journal: (JOURNAL)
- what: The authors report on 20 cases with refractory and/or severe juvenile DM (rsJDM) that received baricitinib combined with tradition drugs in a real-world setting to evaluate its effectiveness and safety in a real-world setting. Frontiers in Pediatrics This study has indicated that baricitinib combined with CS and other immunosuppressants is effective . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.